LifeArc

Another extraordinary week at LifeArc, with the creation of four new LifeArc Translational Centres for Rare Diseases and the first ever LifeArc Translational Science Summit. Both milestones demonstrate the fundamental importance of translational research and its impact on patients, and underline LifeArc’s unique role as a partner for innovation and research. My gratitude goes to our many great teams at LifeArc who made these developments possible, and to the exceptional speakers and delegates for making the summit such a success with inspiring sessions, insightful panels and moving presentations. #LATSS2024

We're still buzzing from the Translational Science Summit. It was incredible to see so many people come together for a day of all things translational science. We've been blown away by all the positive feedback! We'd like to thank all of our incredible speakers for their inspiring and insightful presentations and of course our attendees for your enthusiasm. Together, we made the event a resounding success. For those who missed any sessions or wish to revisit them, recordings of most of the talks will be available on YouTube soon – we'll let you know when they're ready to view. #LATSS2024

That's a wrap on #LATSS2024! Seeing over 700 scientists, experts, policy makers and innovators together discussing translation and life sciences was powerful. There were some fascinating presentations and insightful discussions, and we loved connecting with so many of you. Thank you to all our attendees and to our exceptional speakers for making the day such a success. We look forward to seeing you again next year!

We're excited to announce that we're launching 4 Translational Centres for Rare Diseases! These centres aim to improve diagnostics, encourage new collaborations across disparate research disciplines, bring together leading scientists and unlock new tests, treatments and cures for more than 300 million people living with rare diseases globally. The centres include: 1️⃣ LifeArc Centre for Rare Respiratory Diseases - To create a UK-wide biobank of patient samples and models of disease to enable the advancement of pioneering therapies, and engage with industry and regulatory partners to develop innovative human clinical studies. 2️⃣ LifeArc Kidney Research UK Centre for Rare Kidney Diseases - To unite researchers and patients and build on strongly established resources to improve access to treatments and patient outcomes. 3️⃣ LifeArc Centre for Rare Mitochondrial Diseases - To establish a national platform that will connect patient groups, knowledge and infrastructure to accelerate new treatments getting to clinical trial. 4️⃣ LifeArc Centre for Acceleration of Rare Disease Trials - To improve the efficiency of rare disease trials and increase the number of opportunities for patients to take part. For more details, you can read the full press release here: https://t.ly/YcO-U #GlobalHealth Kidney Research UK, Muscular Dystrophy UK, The Lily Foundation

The Translational Science Summit has begun! Over 800 people are here in person to discuss all things translation and life sciences. Follow the day and share your thoughts over on Twitter/X using #LATSS2024 - https://lnkd.in/eVq3W9wP

Today we announced that Dr Sam Barrell CBE will join LifeArc as CEO in October. Sam joins us from The Francis Crick Institute where we both worked as colleagues. She brings a huge breadth of experience in life sciences and healthcare to LifeArc, and will be a tremendous addition to our team at a time of exciting growth and opportunity for our unique organisation. I look forward to welcoming Sam and to having the opportunity to work together to continue to drive LifeArc forward for the benefit of patients. 

We're delighted to announce the appointment of Dr Sam Barrell CBE as our new Chief Executive Officer.   Sam will join us as CEO on 1 October 2024. Coming from the Francis Crick Institute, she brings over 25 years of experience in the life science and healthcare sectors, as well as expansive knowledge of commercial, digital and health tech, which will be critical to delivering our strategy. https://bit.ly/4d6Z7zi

The countdown is on! Just 5 days until researchers, investors and industry experts from the world of translational science come together at the Translational Science Summit. What's everyone most looking forward to? Don't forget to check the agenda to help you plan your day: https://lnkd.in/eiKQs6pH

The CF AMR Syndicate recently hosted a virtual symposium gathering people with lived experience of cystic fibrosis (CF) and other experts from clinics, academia, industry, and the cystic fibrosis (CF) community to address urgent needs in CF diagnostics. Discussions focused on enhancing exacerbation management, improving pathogen detection and identification, and advancing antimicrobial susceptibility testing, as well as the challenges with current practices, future research directions, and potential opportunities. Key insights from the event include: 1️⃣ The need to adapt clinical practice in line with the evolving CF population due to advancements like Highly Effective Modulator Therapy (HEMT), specifically reducing reliance on sputum samples. 2️⃣ The necessity for developing new diagnostic tests that provide better guidance for intervention strategies during infections and exacerbations. 3️⃣ A move towards more personalized care approaches, enabling better patient involvement in decision-making. 4️⃣ The importance of interdisciplinary collaboration to incorporate the lived experiences of people with CF into diagnostic development. 5️⃣ The significance of interdisciplinary collaboration and incorporating the perspectives of individuals with lived experience of CF throughout diagnostic development. Read the full report to learn more: https://lnkd.in/eC_hNNhG

Take a look at the new #spinout review report commissioned by Government Office for Technology Transfer. It’s fantastic to see the sheer breadth of innovations being developed right across the public sector – https://t.ly/P-8DP